S. Colgan

Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial

J. Statland, M. Pasnoor, J. Verschuuren, 2021, The Lancet Neurology.

Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis

M. Benatar, M. Bromberg, M. Pasnoor, 2020, JAMA neurology.